Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.50 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29804486 | 0.90 | KMO (0.52) | KMOSYKGLSHDAC8HTR2A | |
| SCHEMBL15447295 | 0.90 | KMO (0.52) | KMOSYKGLSHDAC8HTR2A | |
| SCHEMBL539125 | 0.86 | KMO (0.48) | KMOGLSHDAC8HTR2AHTR2C | |
| SCHEMBL21780866 | 0.83 | KMO (0.46) | KMOGLSHDAC8HTR2AHTR2C | |
| SCHEMBL109465 | 0.82 | KMO (0.50) | KMOGLSHDAC8HTR2AHTR2C | |
| SCHEMBL14320695 | 0.81 | CHEK1 (0.48) | KMOSYKGLSHTR2AHTR2C | |
| SCHEMBL13548 | 0.81 | KMO (0.49) | KMOGLSHDAC8HTR2AHTR2C | |
| SCHEMBL21183580 | 0.81 | KMO (0.49) | KMOGLSHDAC8HTR2AHTR2C | |
| SCHEMBL539021 | 0.80 | EGFR (0.46) | KMOEGFR | |
| SCHEMBL29209107 | 0.78 | KMO (0.60) | KMOGLSHDAC8HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1997811-B1 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8017641-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7799782-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-7521447-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039685-A2 | Heterobicyclic compounds as P38 inhibitors | Array Biopharma, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-1997809-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997810-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives for medical use | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997811-A2 | Indazole, benzoxazole and pyrazolopyridine derivatives as P38 kinase inhibitors | Array Biopharma Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA, INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143422-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | KMO 4329/4885SYK 1397/4885GLS 443/4885 |
| US-20090136596-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | KMO 4329/4885SYK 1397/4885GLS 443/4885 |
| US-20090149459-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | MAPKAPK2, MAPK1, MAPK8 | KMO 4329/4885SYK 1397/4885GLS 443/4885 |
| US-20040180896-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | KMO 4027/4885SYK 1071/4885GLS 1081/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | KMO 4027/4885SYK 1071/4885GLS 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.